Thyroid and Hepatic Function After High-Dose 131i-Metaiodobenzylguanidine (131i-Mibg) Therapy for Neuroblastoma

Pediatric Blood and Cancer - United States
doi 10.1002/pbc.22767
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Toxicity of Upfront 131i-Metaiodobenzylguanidine (131i-Mibg) Therapy in Newly Diagnosed Neuroblastoma Patients: A Retrospective Analysis

European Journal of Nuclear Medicine and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
2013English

Experiences From Introducing Standardized High Dose 131i-mIBG Treatment of Children With Refractory Neuroblastoma: Differences in Effective Dose to Patients and Exposure to Caregivers

Journal of Nuclear Medicine & Radiation Therapy
2015English

Effects and Safety of 131i-Metaiodobenzylguanidine (MIBG) Radiotherapy in Malignant Neuroendocrine Tumors: Results From a Multicenter Observational Registry

Endocrine Journal
EndocrinologyMetabolismDiabetes
2014English

Prognostic Values of Initial Responses to Low-Dose 131i-Mibg Therapy in Patients With Malignant Pheochromocytoma and Paraganglioma

Annals of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2013English

Radiation Exposure From Outpatient Radioactive Iodine (131I) Therapy for Thyroid Carcinoma

JAMA - Journal of the American Medical Association
Medicine
2000English

Hypothyroidism and 131I Therapy

BMJ
1968English

Gene Expression Signature in Mouse Thyroid Tissue After 131I and 211At Exposure

EJNMMI Research
Nuclear MedicineRadiologyImaging
2015English

Rat Sodium Iodide Symporter Allows Using Lower Dose of 131I for Cancer Therapy

Gene Therapy
Molecular MedicineGeneticsMolecular Biology
2006English

Efficacy and Affecting Factors of 131I Thyroid Remnant Ablation After Surgical Treatment of Differentiated Thyroid Carcinoma

Frontiers in Oncology
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy